Knowledge, attitudes and practice of pharmacovigilance amongst community pharmacists: a case study of Ogun State, Nigeria

Main Article Content

Sanusi F. Adebukola
Saka S. Ajibola
Amoye O. Alice

Abstract

Background: Medicinal products are among the accomplished successes of the modern health, providing society with enormous benefits. However, medicinal product's known or unknown adverse drug reactions are contributing to deterioration of quality health and wellbeing. Core medicine safety information is generated during clinical trial phase with limitations to the detection of all adverse drug reaction (ADR) due to its restricted period. Pharmacovigilance focuses on detecting and reporting ADRs; hitherto, community pharmacists, often the first point of patients' contact, are preeminent in detecting and reporting ADRs.


Objectives: To assess the knowledge, attitude and the application of pharmacovigilance amongst community pharmacists.


Methods: Cross-sectional survey was conducted among community pharmacists in Ogun State. Data were obtained with a 33 - item self-administered questionnaire and analyzed using descriptive and Chi-square statistics.


Results: Pharmacists' knowledge of pharmacovigilance and reporting of ADRs was adequate as 78.1 % soundly understood pharmacovigilance definition and 73.1 % are knowledgeable about reporting ADRs. The existence of pharmacovigilance centers was confirmed by 81.3 % respondents. The attitudes to pharmacovigilance were positive as 99.6 % believed that the role and utility of pharmacists in ADRs reporting is crucial to their practice. However, 51.9 % had a challenge with time and 96.3 % claimed easy accessibility to reporting forms would facilitate reporting. Age and years of experience of respondents were statistically significant with the knowledge, attitude and practice of pharmacovigilance amongst pharmacists.


Conclusion: There was a relatively good knowledge of pharmacovigilance, and positive attitudes towards ADR reporting; however, time constraints and easy access to reporting forms were barriers to active reporting. 

Downloads

Download data is not yet available.

Article Details

How to Cite
Adebukola, S. F., Ajibola, S. S., & Alice, A. O. (2024). Knowledge, attitudes and practice of pharmacovigilance amongst community pharmacists: a case study of Ogun State, Nigeria. West African Journal of Pharmacy, 35(1), 158-171. https://doi.org/10.60787/wapcp-v35i1-346
Section
Articles

References

Olugbake OA, Rufus AC, Joda A, Balogun M. (2023). Adverse drug reactions reporting by community pharmacists in Lagos State. Ibom Medical Journal 16(2): 176-183.

Santoro A, Genov G, Spooner A, Raine J, Arlett P. (2017). Promoting and protecting public health: How the European Union pharmacovigilance system works. Drug Safety 40(10): 855-869.

SAHPRA. (2021). Post-marketing reporting of adverse drug reactions to human medicines in South Africa. South African Health Products Regulatory Authority, Pretoria, South Africa. Available at: https://www.sahpra.org.za/wpcontent/uploads/2021/10/2.33_Post-MarketingReporting-of-ADRs-to-Human-Medicines-inSA_Version-9.0_October2021.pdf-1.pdf. Accessed December 30, 2023.

SAHPRA. (2022). Post-marketing reporting of adverse drug reactions to human medicines in South Africa. South African Health Products

Regulatory Authority, Pretoria, South Africa. Available at: https://www.sahpra.org.za/wpcontent/uploads/2022/06/SAHPGL-CEM-PV04_Post-Marketing-Reporting-of-ADRs-to-HumanMedicines-in-SA_Version-9.1_June2022.pdf. Accessed December 30, 2023.

Matlala MF, Lubbe MS, Steyn H. (2023). Profile of adverse drug reactions reports in South Africa: An analysis of VigiBase for the year 2017. South African Medical Journal 113(6): 1205-1212.

WHO. (2002). The importance of pharmacovigilance. Safety monitoring of medicinal products. World Health Organization Collaborating

Center for International Drug Monitoring, World Health Organization, Geneva, Switzerland.

FIP. (2006). Statement of policy: The role of the pharmacist in pharmacovigilance. International Pharmaceutical Federation, the Hague, the

Netherlands.

WHO. (2004). Pharmacovigilance: ensuring the safe use of medicines. World Health Organization, Geneva, Switzerland. Available at: https://apps.who.int/iris/bitstream/handle/10665/68782/WHO_EDM_2004.8.pdf?sequence=1&isAllowed=y. Accessed December 31, 2023.

Adisa R, Omitogun TI. (2019). Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and

patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. BMC Health Services Research 19(1): 926. doi:10.1186/s12913-019-4775-9. PMID:31796034;PMCID:PMC6889459.

Abdulsalim S, Farooqui M, Alshammari MS, Alotaibi M, Alhazmi A, Alqasomi A, Altowayan WM. (2023). Evaluation of knowledge, attitudes,

and practices about pharmacovigilance among community pharmacists in Qassim, Saudi Arabia. International Journal of Environmental Research and Public Health 20(4): 3548. https://doi.org/10.3390/ijerph20043548.

Oreagba IA, Ogunleye OJ, Olayemi SO. (2011). The knowledge, perceptions and practice of pharmacovigilance amongst community

pharmacists in Lagos State, South west Nigeria. Pharmacoepidemiology and Drug Safety 20(1): 30-35.

Adedeji WA, Adegoke AB, Fehintola FA. (2021). Adverse drug reactions reporting practice and associated factors among community health

extension workers in public health facilities,Southwest, Nigeria. The Pan African Medical Journal 40: 165-165.

O'Donnell C, Demler TL, Dzierba C. (2022). Perceptions and barriers of adverse drug reaction reporting within inpatient state psychiatric facilities. Mental Health Clinician 12(4): 247-253.

Similar Articles

You may also start an advanced similarity search for this article.